Abstract
Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Current Molecular Medicine
Title: Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Volume: 11 Issue: 9
Author(s): M. Mariani, S. Shahabi, S. Sieber, G. Scambia and C. Ferlini
Affiliation:
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Abstract: Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Export Options
About this article
Cite this article as:
Mariani M., Shahabi S., Sieber S., Scambia G. and Ferlini C., Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?, Current Molecular Medicine 2011; 11 (9) . https://dx.doi.org/10.2174/156652411798062368
DOI https://dx.doi.org/10.2174/156652411798062368 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Astaxanthin Combine with Human Serum Albumin to Abrogate Cell Proliferation, Migration, and Drug-resistant in Human Ovarian Carcinoma SKOV3 Cells
Anti-Cancer Agents in Medicinal Chemistry Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Current Pharmaceutical Design Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Investigation of Isoindolo[2,1-a]quinoxaline-6-imines as Topoisomerase I Inhibitors with Molecular Modeling Methods
Current Computer-Aided Drug Design Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Reviews on Recent Clinical Trials Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Evidence of Green Tea in Targeting Tyrosine Kinases
Current Reviews in Clinical and Experimental Pharmacology Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Synthesis of Oridonin Derivatives via Mizoroki-Heck Reaction and Click Chemistry for Cytotoxic Activity
Anti-Cancer Agents in Medicinal Chemistry Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Recent Developments in Taxane Drug Delivery
Current Drug Delivery